Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...

Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators to treat an increasingly common liver disease, MASH.

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® ...

Novo Nordisk A/S’s weight-loss drug Wegovy has received FDA approval to treat a serious form of liver disease, giving the ...

By Maggie Fick and Diana Novak Jones LONDON (Reuters) -In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and ...

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

COPENHAGEN (Reuters) -Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

The shot was cleared for the disease known as MASH, or metabolic-associated steatohepatitis, in adults with moderate to ...

Decision makes Wegovy the first GLP-1 class therapy cleared for MASH, a liver condition that affects around 5 per cent of ...